VIMIZIM 1 MG
ELOSULFASE ALFA : 1 MG · DIN 02427184 · BIOMARIN INTERNATIONAL LIMITED
Health Canada status: MARKETED
What is VIMIZIM?
VIMIZIM 1 MG contains ELOSULFASE ALFA : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02427184, held by BIOMARIN INTERNATIONAL LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 27-Aug-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VIMIZIM used for?
Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis IVA (Morquio A syndrome, or MPS IVA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02427184 |
|---|---|
| Brand name | VIMIZIM |
| Generic / active ingredient | ELOSULFASE ALFA : 1 MG |
| Manufacturer | BIOMARIN INTERNATIONAL LIMITED |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | A16AB12 ELOSULFASE ALFA |
| AHFS class | 44:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Aug-2014 |
| Original market date | 2014-08-27 00:00:00 |
How is it administered?
2 mg/kg administered once per week via intravenous infusion over approximately 3.5 to 4.5 hours. Pretreatment with antihistamines (with/without antipyretics) is required.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store under refrigeration at 2°C to 8°C. Do not freeze. Protect from light.
How is it supplied?
5 mL vial containing 5 mg elosulfase alfa (1 mg/mL). (Full packaging details like pack size not in snippet).
Contraindications
None listed in the provided Summary Product Information or Contraindications sections.
Warnings and precautions
Boxed Warning: Risk of Anaphylaxis and Hypersensitivity. Life-threatening reactions can occur. Monitor for spinal cord compression and acute respiratory complications.
Who else supplies ELOSULFASE ALFA worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ELOSULFASE ALFA appears in 2 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.